Skip to main content
SpringerLink
Log in

Topische antiangiogene Therapie an der Hornhaut

Sicherheit und Effektivität

Topical inhibition of angiogenesis at the cornea

Safety and efficacy

  • Leitthema
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Sicherheit und Effektivität neuer topischer antiangiogener Therapieansätze an der Hornhaut werden diskutiert.

Methode

Darstellung von eigenen experimentellen und klinischen Ergebnissen sowie Literaturübersicht nach PUBMED Recherche.

Ergebnisse

Sowohl der Off-Label-Gebrauch von Avastin®-Augentropfen als auch die in Phase II getesteten GS101-Augentropfen scheinen eine relativ sichere und effektive Hemmung progressiver kornealer Neovaskularisationen zu ermöglichen. Andere VEGF-Antagonisten wie Pegaptanib- und Ranibizumab-Augentropfen hemmen ebenfalls korneale Neovaskularisation.

Schlussfolgerungen

Mit neuen antiangiogenen Augentropfen steht erstmals eine Möglichkeit zur spezifischen antiangiogenen Therapie an der Hornhaut für den klinischen Einsatz zur Verfügung.

Abstract

Background

The efficacy and safety of novel topical inhibitors of corneal neovascularisation will be discussed.

Methods

A literature review after a PUBMED search and own clinical and experimental results are presented.

Results

The off-label use of Avastin® eye drops and GS101 eye drops against insulin receptor substrate (IRS)-1, which have been tested in phase II trial, both seem to be relatively efficient and safe ways to inhibit progressive corneal neovascularisation. Other VEGF antagonists, such as ranibizumab and pegaptanib eye drops also inhibit corneal neovascularisation.

Conclusions

Avastin® and GS101 eye drops are the first specific angiogenesis inhibitors for topical inhibition of corneal angiogenesis available for clinical use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Cursiefen C, Chen L, Saint-Geniez M et al (2006) Nonvascular VEGFR3 expression by corneal epithelium maintains avascularity and vision. Proc National Acad Sci USA 103:11405–11410

    Article  CAS  Google Scholar 

  2. Cursiefen C (2007) Immune privilege and angiogenic privilege in the cornea. In: Niederkorn J, Kaplan HJ (eds) Immune response and the eye. Chem Immunol Allergy 92:50–57

    Article  PubMed  CAS  Google Scholar 

  3. Cursiefen C, Kruse FE (2006) New aspects of corneal angiogenesis. In: Reinhard T, Larkin F (ed) Cornea and external eye. In Krieglstein GK, Weinreb RN: Essentials in Ophthalmology. Springer, New York 83–99

  4. Cursiefen C, Masli S, Ng TF et al (2004) Roles of thrombospondin 1 and 2 in regulating spontaneous and induced angiogenesis in the cornea and iris. Invest Ophthalmol Vis Sci 45:1117–1124

    Article  PubMed  Google Scholar 

  5. Ambati BK, Nozaki M, Singh N et al (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443:993–997

    Article  PubMed  CAS  Google Scholar 

  6. Cursiefen C, Seitz B, Dana MR,Streilein JW (2003) Angiogenese und Lymphangiogenese in der Hornhaut: Pathogenese, Klinik und Therapieoptionen. Ophthalmologe 100:292–299

    Article  PubMed  CAS  Google Scholar 

  7. Bock F, Koenig Y, Dietrich T et al (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104:336–344

    Article  PubMed  CAS  Google Scholar 

  8. Cursiefen C, Schlötzer-Schrehardt U, Küchle M et al (2002) Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and Podoplanin. Invest Ophthalmol Vis Sci 43:2127–2135

    PubMed  Google Scholar 

  9. Cursiefen C, Maruyama K, Liu Y et al (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45:2666–2673

    Article  PubMed  Google Scholar 

  10. Bachmann B, Bock F, Wiegand S et al (2008) VEGF-A-neutralization after high-risk corneal transplantation promotes graft survival. Arch Ophthalmol 126:71–77

    Article  PubMed  Google Scholar 

  11. Bachmann B, Bock F, Wiegand S et al (2009) Transient VEGF-A-neutralization in corneas with party regressed vessels promotes graft survival. Br J Ophthalmol. (in press)

  12. Chen L, Hamrah P, Cursiefen C et al (2004) Vascular endothelial growth factor receptor-3 (VEGFR-3) mediates dendritic cell migration to lymph nodes and induction of immunity to corneal transplants. Nat Med 10:813–815

    Article  PubMed  CAS  Google Scholar 

  13. Cursiefen C, Chen L, Dana MR, Streilein JW (2003) Corneal lymphangiogenesis: Evidence, mechanisms and implications for transplant immunology. Cornea 22:273–281

    Article  PubMed  Google Scholar 

  14. Cursiefen C, Martus P, Nguyen NX et al (2002) Corneal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty. Cornea 21:648–652

    Article  PubMed  Google Scholar 

  15. Cursiefen C, Wenkel H, Martus P et al (2001) Peripheral corneal neovascularization after non-high risk-keratoplasty: influence of short- versus longtime topical steroids. Graefes Arch Clin Exp Ophthalmol 239:514–521

    Article  PubMed  CAS  Google Scholar 

  16. Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545–2552

    Article  PubMed  Google Scholar 

  17. Bock F, König Y, Kruse FE et al (2008) Bevacizumab (Avastin®) eye drops inhibit corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 246:281–284

    Article  PubMed  CAS  Google Scholar 

  18. Hos D, Bachmann B, Bock F et al (2008) Age-related changes in murine limbal lymphatic vessels and corneal lymphangiogenesis. Exp Eye Res 87:427–432

    Article  PubMed  CAS  Google Scholar 

  19. Bock F, Onderka J, Rummelt C et al (2009) Safety profile of topical VEGF-neutralization at the cornea. Invest Ophthalmol Vis Sci. Epub ahead of print

  20. Bock F, Onderka J, Hos D et al (2008) Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 87:462–470

    Article  PubMed  CAS  Google Scholar 

  21. Regenfuss B, Bock F, Parthasarathy A, Cursiefen C (2008) Corneal (Lymph)angiogenesis-from bedside to bench and back: A tribute to judah folkman. Lymphat Res Biol 6:191–201

    Article  PubMed  Google Scholar 

  22. Yoeruek E, Spitzer MS, Tatar O et al (2007) Safety profile of bevacizumab on cultured human corneal cells. Cornea 26:977–982

    Article  PubMed  Google Scholar 

  23. Kim SW, Ha BJ, Kim EK et al (2008) The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115:e33–e38

    Article  PubMed  Google Scholar 

  24. Cursiefen C, Bock F, Horn F et al (2009) GS-101 eye drops, an antisense oligonucleotide against IRS-1, inhibit corneal neovascularization: interim results of a double-blind randomized phase II trial. Ophthalmology (in revision)

  25. Parthasarathy A, Bock F, Onderka J, Cursiefen C (2009) Lucentis eye drops inhibit inflammatory corneal hem- and lymphangiogenesis. Arch Ophthalmol (in press)

  26. Vinh L, Nguyen N, Martus P et al (2006) Surgery-related factors influencing corneal neovascularization after low-risk keratoplasty. Am J Ophthalmol 141:260–266

    Article  Google Scholar 

  27. Cursiefen C, Rummelt C, Küchle M, Schlötzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87:101–106

    Article  PubMed  CAS  Google Scholar 

  28. König Y, Bock F, Horn F et al (2009) Combination of fine-needle diathermy and Avastin for corneal neovascularization. ARVO

  29. Pillai CT, Dua HS, Hossain P (2000) Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 41:2148–2153

    PubMed  CAS  Google Scholar 

  30. Hos D, Bock F, Dietrich T et al (2008) Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 49:1836–1842

    Article  PubMed  Google Scholar 

  31. Dietrich T, Onderka J, Bock F et al (2007) Inhibition of Inflammatory Lymphangiogenesis by Integrin {alpha}5 Blockade. Am J Pathol 171:361–372

    Article  PubMed  CAS  Google Scholar 

  32. Cursiefen C, Kruse FE, Naumann GOH (2008) Cornea and limbus. In: GOH Naumann. Applied pathology for ophthalmic microsurgeons. Springer, New York 97–130

  33. Maruyama K, Li M, Cursiefen C et al (2004) Inflammatory lymphangiogenesis arises from CD11b+ cells. J Clin Invest 15:2363–2372

    Google Scholar 

Download references

Interessenkonflikt

Seniorautor ist Berater der Firma Gene Sionac, Frankreich.

Author information

Authors and Affiliations

  1. Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Deutschland

    B. Regenfuss, F. Bock, B. Bachmann, Y. König, D. Hos &  C. Cursiefen

  2. Singapore National Eye Center, Singapore Eye Research Institute, Singapur, Singapur

    A. Parthasarathy

  3. Für die 3GS101 Studiengruppe: Horn FK, Kunze M, Kruse FE, Vogler M, Strahwald H, Seitz B, Schirra F, Borderie V, Früh B, Thiel MA, Wilhelm F, Geudelin B, Descohand I, Steuhl KP, Hahn A, Meller D, Erlangen, Deutschland

    C. Cursiefen

Authors
  1. B. Regenfuss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Bock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Bachmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. König
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Hos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Parthasarathy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Cursiefen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Cursiefen.

Additional information

Unterstützung: DFG (Sonderforschungsbereich 643; Projekt B10), Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Erlangen (Projekt A9).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Regenfuss, B., Bock, F., Bachmann, B. et al. Topische antiangiogene Therapie an der Hornhaut. Ophthalmologe 106, 399–406 (2009). https://doi.org/10.1007/s00347-009-1934-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-009-1934-0

Schlüsselwörter

Keywords

Search

Navigation